Oral dimethyl fumarate (BG-12) is in development for the treatment of relapsing multiple sclerosis (MS), though experimental evidence already suggests it may provide anti-inflammatory and cytoprotective effects by activating the transcription factor Nrf2.
While phenotypes of multiple sclerosis (MS) are well-established, there remains heterogeneity among patients that fit existing clinical definitions.
Compared with placebo, teriflunomide was shown to significantly reduce the occurrence of relapses with sequelae and relapses treated with corticosteroids in a post-hoc analysis of pivotal clinical trial data.
Data presented at the 2013 AAN Annual Meeting indicate that MAP0004, which delivers dihydroergotamine (DHE) via oral inhalation, is effective in the acute treatment of severe migraine pain.
Study results show a novel formulation of oxcarbazepine may provide long-term seizure reduction in patients with refractory epilepsy, while a separate trial produced promising results for long-term lacosamide treatment in elderly patients with partial-onset seizures.
Severe neuropathic pain due to diabetic peripheral neuropathy is associated with negative health impact and increased healthcare utilization, underscoring the need for the development of safe and effective treatments.
Ability to differentiate between subtypes of frontotemporal lobar degeneration could accelerate research into the pathology and prevention of this disease and aid in the design of disease-modifying therapies.